Arcus Biosciences is a pioneering biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. With a robust pipeline that includes treatments like Domvanalimab and AB308 for advanced cancers, and Etrumadenant for dual adenosine receptor antagonism, the company is at the forefront of clinical trials aimed at combating various malignancies. Additionally, Arcus is exploring treatments for inflammatory diseases in collaboration with industry leaders, demonstrating its commitment to advancing healthcare through groundbreaking research.
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a stake.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
In a world where investors are starving to find growth, many of the well established biotech leaders and many of the large pharmaceutical companies have been acquiring growth on top of their…
